mutation predictions | marginal predictions | summary statistics | genome diff | command line log
|
breseq version 0.35.4 revision f352f80f4bc9
mutation predictions | marginal predictions | summary statistics | genome diff | command line log |
| Marginal read alignment evidence | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| seq id | position | ref | new | freq | score (cons/poly) | reads | annotation | genes | product | ||
| * | NC_000913_3_bme_pgi | 526,792 | 0 | A | C | 38.5% | 29.1 / 53.4 | 53 | S1178R (AGC→CGC) | rhsD | Rhs protein with DUF4329 family putative toxin domain; putative neighboring cell growth inhibitor |
| * | NC_000913_3_bme_pgi | 526,800 | 0 | A | G | 38.5% | 52.8 / 46.2 | 53 | E1180E (GAA→GAG) | rhsD | Rhs protein with DUF4329 family putative toxin domain; putative neighboring cell growth inhibitor |
| * | NC_000913_3_bme_pgi | 526,796 | 0 | C | G | 37.7% | 57.2 / 58.9 | 53 | A1179G (GCG→GGG) | rhsD | Rhs protein with DUF4329 family putative toxin domain; putative neighboring cell growth inhibitor |
| Marginal new junction evidence (lowest skew 10 of 119 shown) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| seq id | position | reads (cov) | reads (cov) | score | skew | freq | annotation | gene | product | ||
| * | ? | NC_000913_3_bme_pgi | = 4040689 | 32 (1.020) | 6 (0.190) | 6/284 | 3.2 | 18.9% | intergenic (+53/+217) | rrfA/mobB | 5S ribosomal RNA of rrnA operon/molybdopterin‑guanine dinucleotide biosynthesis protein B |
| ? | NC_000913_3_bme_pgi | = 4213156 | 20 (0.650) | noncoding (117/120 nt) | rrfE | 5S ribosomal RNA of rrnE operon | |||||
| * | ? | NC_000913_3_bme_pgi | = 1715918 | 28 (0.890) | 4 (0.140) | 4/266 | 3.8 | 13.2% | intergenic (‑29/+30) | pdxY/tyrS | pyridoxamine kinase/tyrosyl‑tRNA synthetase |
| ? | NC_000913_3_bme_pgi | = 1715922 | 27 (0.930) | intergenic (‑33/+26) | pdxY/tyrS | pyridoxamine kinase/tyrosyl‑tRNA synthetase | |||||
| * | ? | NC_000913_3_bme_pgi | 3470277 = | NA (NA) | 4 (0.130) | 4/274 | 3.9 | NA | coding (1053/1185 nt) | tufA | translation elongation factor EF‑Tu 1 |
| ? | NC_000913_3_bme_pgi | 3470311 = | NA (NA) | coding (1019/1185 nt) | tufA | translation elongation factor EF‑Tu 1 | |||||
| * | ? | NC_000913_3_bme_pgi | = 3353476 | 37 (1.180) | 4 (0.130) | 4/274 | 3.9 | 10.6% | coding (575/930 nt) | yhcC | putative Fe‑S oxidoreductase, Radical SAM superfamily protein |
| ? | NC_000913_3_bme_pgi | = 3353484 | 32 (1.070) | coding (567/930 nt) | yhcC | putative Fe‑S oxidoreductase, Radical SAM superfamily protein | |||||
| * | ? | NC_000913_3_bme_pgi | 1449791 = | 38 (1.210) | 4 (0.140) | 4/272 | 3.9 | 9.8% | coding (1559/2274 nt) | tynA | tyramine oxidase, copper‑requiring |
| ? | NC_000913_3_bme_pgi | 1449816 = | 38 (1.280) | coding (1534/2274 nt) | tynA | tyramine oxidase, copper‑requiring | |||||
| * | ? | NC_000913_3_bme_pgi | = 551487 | NA (NA) | 4 (0.130) | 4/274 | 3.9 | 9.3% | noncoding (134/157 nt) | REP52 (repetitive extragenic palindromic) element; contains 4 REP sequences | REP52 (repetitive extragenic palindromic) element; contains 4 REP sequences |
| ? | NC_000913_3_bme_pgi | = 4027398 | 39 (1.310) | noncoding (77/281 nt) | REP291 (repetitive extragenic palindromic) element; contains 6 REP sequences | REP291 (repetitive extragenic palindromic) element; contains 6 REP sequences | |||||
| * | ? | NC_000913_3_bme_pgi | = 551487 | NA (NA) | 4 (0.130) | 4/274 | 3.9 | 8.0% | noncoding (134/157 nt) | REP52 (repetitive extragenic palindromic) element; contains 4 REP sequences | REP52 (repetitive extragenic palindromic) element; contains 4 REP sequences |
| ? | NC_000913_3_bme_pgi | 2316890 = | 46 (1.540) | noncoding (57/197 nt) | RIP162 (repetitive extragenic palindromic) element; contains 5 REP sequences and 1 IHF site | RIP162 (repetitive extragenic palindromic) element; contains 5 REP sequences and 1 IHF site | |||||
| * | ? | NC_000913_3_bme_pgi | 375132 = | 53 (1.690) | 4 (0.130) | 4/274 | 3.9 | 7.4% | noncoding (203/436 nt) | REP31 (repetitive extragenic palindromic) element; contains 9 REP sequences | REP31 (repetitive extragenic palindromic) element; contains 9 REP sequences |
| ? | NC_000913_3_bme_pgi | = 3512570 | NA (NA) | noncoding (60/90 nt) | REP250 (repetitive extragenic palindromic) element; contains 2 REP sequences | REP250 (repetitive extragenic palindromic) element; contains 2 REP sequences | |||||
| * | ? | NC_000913_3_bme_pgi | = 1670967 | 17 (0.540) | 4 (0.140) | 3/262 | 4.2 | 19.8% | intergenic (+15/‑409) | ynfM/asr | putative arabinose efflux transporter/acid shock‑inducible periplasmic protein |
| ? | NC_000913_3_bme_pgi | = 1670981 | 17 (0.600) | intergenic (+29/‑395) | ynfM/asr | putative arabinose efflux transporter/acid shock‑inducible periplasmic protein | |||||
| * | ? | NC_000913_3_bme_pgi | = 3345001 | 16 (0.510) | 3 (0.100) | 3/268 | 4.3 | 15.0% | coding (285/1434 nt) | rpoN | RNA polymerase, sigma 54 (sigma N) factor |
| ? | NC_000913_3_bme_pgi | = 3345013 | 19 (0.650) | coding (297/1434 nt) | rpoN | RNA polymerase, sigma 54 (sigma N) factor | |||||